Targeting the GAS6-AXL pathway!

Transfer from | Pharmaceutical Mission Hills

On July 6, 3D Medicines announced that its subsidiary, 3D Medicines 3D229 injection, has been approved by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration, and has joined the global international multi-center phase 3 clinical trial

Studies have shown that the GAS6-AXL signaling pathway is a key pathway that promotes tumor growth and metastasis, tumor immune escape and drug tolerance

According to reports, 3D229 is a recombinant fusion protein targeting the GAS6-AXL pathway

According to reports, this time approved in China is a randomized, double-blind, controlled, adaptive phase 3 clinical study, which aims to evaluate the effectiveness and safety of 3D229 combined with paclitaxel in the treatment of platinum-resistant recurrent ovarian cancer.

In a number of clinical trials, 3D229 has demonstrated good safety and anti-tumor efficacy

Ovarian cancer is one of the most common gynecological malignancies, and it is also a gynecological tumor with a higher mortality rate

Original title: Introduction of over 200 million US dollars! Siddi Pharmaceutical's GAS6/AXL inhibitor was approved for Phase 3 clinical trials in China